CJC-1295 + Ipamorelin vs Tesamorelin: What the Research Shows
CJC-1295 + Ipamorelin and Tesamorelin side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider CJC-1295 + Ipamorelin if…
No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.
Consider Tesamorelin if…
- you want a product with an FDA label: Egrifta is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management[9]
- you want randomized data in HIV-associated lipodystrophy: Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment.[15]
What they have in common
- WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin[2]
Spec comparison
Showing 9 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.
| Field | CJC-1295 + Ipamorelin | Tesamorelin |
|---|---|---|
| Class | GHRH + GHRP blend | GHRH analog |
| Also called | CJC/Ipa | tesa, Egrifta |
| Category | Growth hormone | Growth hormone |
| FDA status | Not FDA approved · research blend | FDA approved (Egrifta) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times. | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. |
| Anti-doping detection |
|
|
| Half-life | Ipamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) |
| Evidence strength | Human RCT evidence, 4 of 4Ipamorelin: International journal of colorectal disease 2014, PMID 25331030 | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 |
| Human studies we summarised | 6 human (3 randomized or controlled) of 19 summarised, across ingredients | 12 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 10 mg | 2 mg, 5 mg, 10 mg, 20 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
CJC-1295 + Ipamorelin and Tesamorelin together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 6 results, 2 Oct 2026).
CJC-1295 and ipamorelin versus tesamorelin: what the trials measured
Tesamorelin has randomized trials beyond HIV lipodystrophy. One enrolled 60 abdominally obese adults with reduced GH secretion.[16]
In that trial, tesamorelin selectively reduced visceral fat without significant effects on subcutaneous fat.[16]
In the same trial, no changes in fasting glucose, 2-h glucose or glycated hemoglobin were seen.[16]
In a randomized trial of tesamorelin in adults with mild cognitive impairment and healthy older adults, IGF-1 rose by 117% and body fat fell by 7.4%.[17]
Ipamorelin's efficacy trial found no significant differences from placebo in the key and secondary analyses.[5]
What the tesamorelin label contributes
The Egrifta WR label says to store the 11.6 mg vial at room temperature, 20°C to 25°C, in the original box to protect from light.[9]
The label says Egrifta WR is not indicated for weight loss management because it has a weight neutral effect.[9]
Common questions
CJC-1295 ipamorelin vs tesamorelin: which burns more belly fat?
Tesamorelin's randomized trials measured visceral fat, in HIV lipodystrophy and in obese adults with reduced GH secretion; it selectively reduced visceral fat in the latter.[16]
Is tesamorelin the same kind of drug as CJC-1295?
The cited trial describes tesamorelin as a GHRH(1-44) analog given at 2 mg once daily for 12 months.[16]
Does tesamorelin affect blood sugar?
In the obese-adult trial, no changes in fasting glucose, 2-h glucose or glycated hemoglobin were seen.[16]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 4Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 5Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 6Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 7An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 8Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 9EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 10The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 11Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 12The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 13PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 16Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
- 17Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.Archives of neurology · 2012PMID 22869065Accessed 2 Oct 2026
Found an error? Report a correction.